Encelo Laboratories

Executive Summary

Encelo Laboratories is a UK-based biotech company pioneering non-invasive access to human cells for precision medicine through its proprietary Cell Catcher device. This point-of-care platform enables simple, at-home collection and preservation of live cells from urine, addressing critical limitations of traditional methods—such as short shelf life and low cell yield—while providing scalable, patient-specific biomaterial for applications in drug delivery, diagnostics, and biologics. Since its founding in 2020, Encelo has focused on overcoming the logistical barriers of cell-based precision medicine, aiming to democratize access to high-quality cellular samples without the need for invasive procedures. The company's technology has the potential to transform the collection of urological and systemic biomarkers, enabling earlier detection, personalized treatment, and more efficient clinical trials. As a private entity with no disclosed funding or revenue, Encelo is in an early-stage development phase and is likely seeking strategic partnerships or regulatory clearances to validate its platform and secure growth capital.

Upcoming Catalysts (preview)

• Q3 2026Regulatory submission for Cell Catcher (UKCA or CE marking)55% success
• Q4 2026Strategic partnership with a pharmaceutical company for clinical trial integration40% success
• Q4 2026Series A funding round to support commercial scale-up50% success